Allspring Global Investments Holdings LLC Sells 10,424 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Allspring Global Investments Holdings LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,002 shares of the medical research company's stock after selling 10,424 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in IQVIA were worth $12,488,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Smith Group Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth about $1,616,000. Simplify Asset Management Inc. increased its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares during the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Fifth Third Bancorp increased its holdings in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS increased its holdings in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after buying an additional 2,700 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Down 0.2 %

Shares of NYSE IQV traded down $0.46 during mid-day trading on Friday, reaching $193.55. The company had a trading volume of 166,906 shares, compared to its average volume of 1,365,314. The stock has a market capitalization of $34.08 billion, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock's 50 day moving average is $199.73 and its 200-day moving average is $216.79. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John G. Danhakl purchased 1,275 shares of the firm's stock in a transaction on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. TD Cowen lowered their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Barclays reduced their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird cut their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus target price of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.